Literature DB >> 33659946

The role of vitamin D in sarcoidosis.

Fabiola Gianella1, Connie Cw Hsia1,2, Khashayar Sakhaee3,2.   

Abstract

After the initial description of extrarenal synthesis of 1,25-dihydroxyvitamin D (1,25-(OH)2D) three decades ago, extensive progress has been made in unraveling the immunomodulatory roles of vitamin D in the pathogenesis of granulomatous disorders, including sarcoidosis. It has been shown that 1,25-(OH)2D has dual effects on the immune system, including upregulating innate immunity as well as downregulating the autoimmune response. The latter mechanism plays an important role in the pathogenesis and treatment of sarcoidosis. Vitamin D supplementation in patients with sarcoidosis has been hampered owing to concerns about the development of hypercalcemia and hypercalciuria given that extrarenal 1-α hydroxylase is substrate dependent. Recently, a few studies have cast doubt over the mechanisms underlying the development of hypercalcemia in this population. These studies demonstrated an inverse relationship between the level of vitamin D and severity of sarcoidosis. Consequently, clinical interest has been piqued in the use of vitamin D to attenuate the autoimmune response in this disorder. However, the development of hypercalcemia and the attendant detrimental effects are real possibilities. Although the average serum calcium concentration did not change following vitamin D supplementation, in two recent studies, hypercalciuria occurred in one out of 13 and two out of 16 patients. This review is a concise summary of the literature, outlining past work and newer developments in the use of vitamin D in sarcoidosis. We feel that larger-scale placebo-controlled randomized studies are needed in this population. Since the current first-line treatment of sarcoidosis is glucocorticoids, which confer many systemic adverse effects, and steroid-sparing immunosuppressant treatment options carry additional risks of adverse effects, adjunct management with vitamin D in combination with potent anti-osteoporotic medications could minimize the risk of glucocorticoid-induced osteoporosis and modulate the immune system to attenuate disease activity in sarcoidosis. Copyright:
© 2020 Sakhaee K et al.

Entities:  

Keywords:  Sarcoidosis; autoimmune; hypercalcemia; kidney stones; vitamin D

Year:  2020        PMID: 33659946      PMCID: PMC7886067          DOI: 10.12703/b/9-14

Source DB:  PubMed          Journal:  Fac Rev        ISSN: 2732-432X


  2 in total

Review 1.  The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.

Authors:  Julie H Wu; Sotonye Imadojemu; Avrom S Caplan
Journal:  Am J Clin Dermatol       Date:  2022-05-18       Impact factor: 6.233

Review 2.  A Narrative Review of the Evidence for Variations in Serum 25-Hydroxyvitamin D Concentration Thresholds for Optimal Health.

Authors:  William B Grant; Fatme Al Anouti; Barbara J Boucher; Erdinç Dursun; Duygu Gezen-Ak; Edward B Jude; Tatiana Karonova; Pawel Pludowski
Journal:  Nutrients       Date:  2022-02-02       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.